CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
No open-market purchases or sales by CytomX Therapeutics, Inc. insiders were filed in the last 90 days; 178 institutions reported holding it in 13F filings for Q2 2026, worth $799.0M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in CytomX Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 178
- +1 vs. Q1 2026
- Shares held
- 213.0M
- +19.3M (+9.9%) vs. Q1 2026
- Total value
- $799.0M
- −$111.7M (−12.3%) vs. Q1 2026
- New holders
- 46
- 70 more added
- Sold out
- 45
- 33 more reduced
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CTMX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 178 | $799.0M |
| Q1 2026 | 179 | $911.2M |
| Q4 2025 | 122 | $613.9M |
| Q3 2025 | 103 | $438.4M |
| Q2 2025 | 83 | $302.6M |
| Q1 2025 | 66 | $28.8M |
| Q4 2024 | 70 | $48.1M |
| Q3 2024 | 69 | $60.4M |
| Q2 2024 | 74 | $61.9M |
| Q1 2024 | 88 | $97.1M |
| Q4 2023 | 68 | $50.6M |
| Q3 2023 | 62 | $41.8M |
| Q2 2023 | 67 | $58.7M |
| Q1 2023 | 76 | $53.7M |
| Q4 2022 | 81 | $57.5M |
| Q3 2022 | 84 | $52.6M |
| Q2 2022 | 99 | $83.4M |
| Q1 2022 | 119 | $143.4M |
| Q4 2021 | 110 | $236.5M |
| Q3 2021 | 114 | $274.8M |
| Q2 2021 | 122 | $358.9M |
| Q1 2021 | 126 | $422.2M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding CytomX Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −68,378−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −67,732−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −63,694−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −62,400−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −57,475−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −51,600−100.0% | Sold out |
| HB Wealth Management, LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Toronto Dominion Bank | 0 | $0 | 0.00% | −40,116−100.0% | Sold out |
| Gabelli Funds LLC | 0 | $0 | 0.00% | −33,000−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −33,920−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −31,100−100.0% | Sold out |
| Mangrove Partners | 0 | $0 | 0.00% | −26,265−100.0% | Sold out |
| Ethos Financial Group, LLC | 0 | $0 | 0.00% | −23,697−100.0% | Sold out |
| Mariner, LLC | 0 | $0 | 0.00% | −19,750−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −19,140−100.0% | Sold out |
| Sanctuary Advisors, LLC | 0 | $0 | 0.00% | −17,053−100.0% | Sold out |
| Evolve Private Wealth, LLC | 0 | $0 | 0.00% | −14,833−100.0% | Sold out |
| Gabelli & Co Investment Advisers, Inc. | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −10,505−100.0% | Sold out |
| Lido Advisors, LLC | 0 | $0 | 0.00% | −10,425−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −529−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −274−100.0% | Sold out |
| Rachor Investment Advisory Services, LLC | 0 | $0 | 0.00% | −175−100.0% | Sold out |
| Skopos Labs, Inc. | – | – | – | – | Not filed |
| Janus Henderson Group PLC | – | – | – | – | Not filed |